Nektar Therapeutics (NKTR) released Loss for its first quarter that increased from last year and missed the Street estimates.
The company's bottom line came in at -$50.88 million, or -$0.24 per share. This compares with -$36.80 million, or -$0.19 per share, last year.
Analysts on average had expected the company to earn -$0.19 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period fell 51.7% to $10.460 million from $21.639 million last year.
Nektar Therapeutics earnings at a glance (GAAP) :
-Earnings: -$50.88 Mln. vs. -$36.80 Mln. last year.
-EPS: -$0.24 vs. -$0.19 last year.
-Revenue: $10.460 Mln vs. $21.639 Mln last year.
For comments and feedback: editorial@rttnews.com